145 related articles for article (PubMed ID: 31099295)
21. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
[TBL] [Abstract][Full Text] [Related]
22. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
24. Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Piek JM
Int J Gynecol Cancer; 2013 Oct; 23(8):1348. PubMed ID: 24257547
[No Abstract] [Full Text] [Related]
25. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer.
Zhang Y; Chen Q
Braz J Med Biol Res; 2017 May; 50(6):e6104. PubMed ID: 28538838
[TBL] [Abstract][Full Text] [Related]
26. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
27. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R
Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637
[TBL] [Abstract][Full Text] [Related]
28. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
29. Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.
Chmelarova M; Baranova I; Ruszova E; Laco J; Hrochova K; Dvorakova E; Palicka V
Pathol Oncol Res; 2019 Oct; 25(4):1457-1465. PubMed ID: 30368729
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
[TBL] [Abstract][Full Text] [Related]
32. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
33. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma.
Krigman HR; Coogan AC; Marks JR
Arch Pathol Lab Med; 1995 Jan; 119(1):99-103. PubMed ID: 7802567
[TBL] [Abstract][Full Text] [Related]
35. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
36. Increased DHRS12 expression independently predicts poor survival in patients with high-grade serous ovarian cancer.
Zhang Y; Wu J; Jing H; Huang G; Dong J; Cui Z
Future Oncol; 2018 Oct; 14(25):2579-2588. PubMed ID: 29783891
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
Sabatier R; Calderon B; Lambaudie E; Chereau E; Provansal M; Cappiello MA; Viens P; Rousseau F
Int J Gynecol Cancer; 2015 Jun; 25(5):815-22. PubMed ID: 25768081
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
[TBL] [Abstract][Full Text] [Related]
39. Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.
Li H; Xiao N; Li Z; Wang Q
Tohoku J Exp Med; 2017 Feb; 241(2):165-173. PubMed ID: 28202851
[TBL] [Abstract][Full Text] [Related]
40. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]